Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.

Merle, Philippe; Kudo, Masatoshi; Krotneva, Stanimira; Ozgurdal, Kirhan; Su, Yun; Proskorovsky, Irina

Merle, Philippe; Kudo, Masatoshi; Krotneva, Stanimira; Ozgurdal, Kirhan; Su, Yun; Proskorovsky, Irina.

Afiliação

Merle P; Hepatology and Gastroenterology Unit, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France, INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Krotneva S; Evidera, Montreal, Québec, Canada.
Ozgurdal K; Bayer Consumer Care AG, Basel, Switzerland.
Su Y; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Proskorovsky I; Evidera, Montreal, Québec, Canada.

Liver Cancer ; 12(2): 145-155, 2023 Jun.

Article em En | MEDLINE | ID: mdl-37325487

Palavras-chave

Cabozantinib; Decision-making; Hepatocellular carcinoma; Indirect treatment comparison; Regorafenib; Tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Liver Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google